B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

BMPR1B

MOLECULAR TARGET

bone morphogenetic protein receptor type 1B

UniProt: O00238NCBI Gene: 65826 compounds

BMPR1B (bone morphogenetic protein receptor type 1B) is targeted by 26 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting BMPR1B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1sb 2035804.92136
2alvocidib4.5291
3tozasertib4.3375
4vandetanib4.3073
5ruxolitinib4.2368
6quizartinib3.9953
7pazopanib3.6939
8canertinib3.5333
9tae 6843.4330
10fedratinib3.4029
11gilteritinib3.4029
12linifanib3.3327
13mln 80543.3327
14saracatinib3.3327
15dorsomorphin3.1422
16at 92833.0921
17lestaurtinib3.0420
18momelotinib2.8917
19r 4062.8316
20plx 47202.7114
21kw 24492.6413
22tak 2852.4010
23su 0148132.208
24asp 30262.087
25Axitinib0.691
26Crizotinib0.691

About BMPR1B as a Drug Target

BMPR1B (bone morphogenetic protein receptor type 1B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 26 compounds with documented BMPR1B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

BMPR1B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.